Rocket Pharma announced positive initial safety data for the first three patients in its pivotal Phase 2 trial for RP-A501 in Danon disease, with no significant adverse events observed. The company is engaging with the FDA to finalize the path for trial completion, with a regulatory update expected in H2 2026. This positive safety update reduces a key risk for the drug's development.
Rocket Pharma reported that the initial three patients treated with RP-A501 for Danon disease under a modified protocol showed positive safety, with no thrombotic microangiopathy (TMA) or capillary leak syndrome observed. This is a crucial de-risking event for the drug, as previous safety concerns have been a hurdle. The company is now actively working with the FDA to align on the path to completing the pivotal Phase 2 trial, with regulatory and program updates anticipated in the second half of 2026. This news is a short-term positive for RCKT, as it addresses a significant safety overhang and provides a clearer path forward for a potentially transformative therapy for Danon disease. The long-term implications depend on the full trial results and regulatory approval, but this initial safety data is a strong positive signal.